Pdf/Prescribing Information.Pdf [Last Accessed 14 March 2014] Served As an Expert Consultant in a Medicolegal Case

Total Page:16

File Type:pdf, Size:1020Kb

Pdf/Prescribing Information.Pdf [Last Accessed 14 March 2014] Served As an Expert Consultant in a Medicolegal Case Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: http://www.tandfonline.com/loi/icmo20 An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions Gary L. Pattee, James P. Wymer, Catherine Lomen-Hoerth, Stanley H. Appel, Andrea E. Formella & Laura E. Pope To cite this article: Gary L. Pattee, James P. Wymer, Catherine Lomen-Hoerth, Stanley H. Appel, Andrea E. Formella & Laura E. Pope (2014) An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions, Current Medical Research and Opinion, 30:11, 2255-2265, DOI: 10.1185/03007995.2014.940040 To link to this article: https://doi.org/10.1185/03007995.2014.940040 © 2014 The Author(s). Published by Taylor & View supplementary material Francis. Accepted author version posted online: 25 Submit your article to this journal Jul 2014. Published online: 28 Jul 2014. Article views: 1684 View related articles View Crossmark data Citing articles: 11 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=icmo20 Download by: ["University at Buffalo Libraries"] Date: 28 November 2017, At: 19:52 Current Medical Research & Opinion Vol. 30, No. 11, 2014, 2255–2265 0300-7995 Article FT-0229.R1/940040 doi:10.1185/03007995.2014.940040 All rights reserved: reproduction in whole or part not permitted Original article An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions Gary L. Pattee Abstract Neurology Associates, Lincoln, NE, USA Background: James P. Wymer Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and The Neurosciences Institute, Albany Medical Center, characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or Albany, NY, USA unrelated to the patient’s emotional state. Clinical trials establishing dextromethorphan and quinidine Catherine Lomen-Hoerth (DM/Q) as PBA treatment were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple Department of Neurology, University of California, San sclerosis (MS). This trial evaluated DM/Q safety in patients with PBA secondary to any neurological condition Francisco, CA, USA affecting the brain. Stanley H. Appel Department of Neurology, Methodist Neurological Objective: Institute, The Methodist Hospital Research Institute, To evaluate the safety and tolerability of DM/Q during long-term administration to patients with PBA The Methodist Hospital, Houston, TX, USA associated with multiple neurological conditions. Andrea E. Formella Methods: Laura E. Pope Fifty-two-week open-label study of DM/Q 30/30 mg twice daily. Safety measures included adverse events Avanir Pharmaceuticals Inc., Aliso Viejo, CA, USA (AEs), laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations. Address for correspondence: Clinical trial registration: Gary L. Pattee MD, Neurology Associates, PC, 2631 #NCT00056524. South 70th Street, Lincoln, NE 68506, USA. Tel.: +1 402 483 7226; Fax: +1 402 483 5440; [email protected] Results: Downloaded by ["University at Buffalo Libraries"] 19:52 28 November 2017 A total of 553 PBA patients with430 different neurological conditions enrolled; 296 (53.5%) completed. The most frequently reported treatment-related AEs (TRAEs) were nausea (11.8%), dizziness (10.5%), headache Keywords: (9.9%), somnolence (7.2%), fatigue (7.1%), diarrhea (6.5%), and dry mouth (5.1%). TRAEs were mostly Dextromethorphan/quinidine – Pseudobulbar affect – Safety – Tolerability mild/moderate, generally transient, and consistent with previous controlled trials. Serious AEs (SAEs) were reported in 126 patients (22.8%), including 47 deaths, mostly due to ALS progression and respiratory Accepted: 26 June 2014; published online: 28 July 2014 failure. No SAEs were deemed related to DM/Q treatment by investigators. ECG results suggested no Citation: Curr Med Res Opin 2014; 30:2255–65 clinically meaningful effect of DM/Q on myocardial repolarization. Differences in AEs across neurological disease groups appeared consistent with the known morbidity of the primary neurological conditions. Study interpretation is limited by the small size of some disease groups, the lack of a specific efficacy measure and the use of a DM/Q dose higher than the eventually approved dose. Conclusions: DM/Q was generally well tolerated over this 52 week trial in patients with PBA associated with a wide range of neurological conditions. ! 2014 Informa UK Ltd www.cmrojournal.com Safety of dextromethorphan/quinidine in PBA Pattee et al. 2255 Current Medical Research & Opinion Volume 30, Number 11 November 2014 Introduction were instructed to take DM/Q 30/30 mg in the evening for 7 days and then twice daily thereafter. Patients kept a Pseudobulbar affect (PBA) is a neurological condition that diary of dosage times and recorded any adverse events exerts a significant health burden on patients and care- (AEs). Clinic visits occurred at screening, baseline 1 givers . PBA is associated with a wide range of neuro- (Day 1), and after 1, 4, 8, and 12 months of treatment or logical disorders and is characterized by frequent, sudden, at patient discontinuation. During months when no clinic uncontrollable episodes of crying and/or laughing that are visit was scheduled, patients were contacted by telephone greatly exaggerated or contrary to the patient’s emotional and asked about medication compliance and AEs. state2. Available prevalence studies suggest PBA is present in at least 5% of Parkinson’s disease (PD), 10% of multiple sclerosis (MS), stroke, traumatic brain injury (TBI), and Study population Alzheimer’s disease (AD), 20% of progressive supranuclear palsy, and up to 50% of amyotrophic lateral sclerosis Eligible patients were 18 to 75 years of age with a clinical (ALS) patients3–11. diagnosis of PBA. For the purposes of this study, PBA was PBA is thought to arise from disruption of corticobulbar defined as ‘a syndrome characterized by outbursts of crying and cerebellar/pontine pathways controlling emotional and/or laughing that occur spontaneously and inappropri- expression12–14. These pathways may be disrupted by mul- ately given the context in which they occur’. No specific tiple neurological conditions, yet the ensuing clinical threshold for severity of PBA symptoms was required for manifestations of PBA are indistinguishable, consistent study entry. Patients were required to have an electrocar- with a common etiology across disorders12–14. The com- diogram (ECG) with no evidence of rate-corrected QT bination of dextromethorphan and quinidine (DM/Q) is interval (QTc) prolongation (450 msec in men; the first pharmacotherapy approved by the US Food and 470 msec in women), heart block (isolated right bundle Drug Administration (FDA) and European Medicines branch block without clinical history of heart disease was Authority (EMA) for treating PBA15,16. allowable), sinus bradycardia (550 bpm), ventricular Dextromethorphan (DM) has many pharmacological tachycardia, multifocal ventricular ectopic beats (any fre- actions, including uncompetitive N-methyl-D-aspartate quency), or unifocal ventricular ectopic beats (45/min). (NMDA) receptor antagonism17, sigma-1 receptor agon- Patients with ALS were required to have a vital capacity ism18, and serotonin reuptake inhibition, among others; 50% at baseline. Patients completing prior controlled the precise mechanism(s) accounting for PBA suppression studies of twice daily DM/Q 30/30 mg to treat PBA in 23 22 is/are unknown19. DM is co-administered with low-dose MS or ALS were also eligible to participate, provided quinidine, a potent CYP2D6 inhibitor that reduces rapid they met all eligibility requirements at the time of enroll- first-pass metabolism of DM. This inhibition increases DM ment in this study. bioavailability and half-life20,21. The efficacy, safety, and Exclusion criteria were myasthenia gravis; a history of tolerability of DM/Q as PBA treatment was established in ventricular tachycardia or torsades de pointes; sensitivity three controlled clinical trials lasting 422 or 1223,24 weeks, to quinidine or opiate drugs; major psychiatric disturbance; using fixed-dose combinations of twice daily DM/Q 30/ a history of substance abuse in the past 2 years; any major 30 mg22,23, 30/10 mg24, or 20/10 mg24 in patients with systemic disease that would interfere with interpretation of ALS22,24 or MS23,24. The present trial was designed to pro- study results (e.g., malignancy, uncontrolled diabetes, vide long-term safety data using the higher DM/Q 30/ dilated cardiac myopathy, ischemic or valvular heart Downloaded by ["University at Buffalo Libraries"] 19:52 28 November 2017 30 mg dose in patients with PBA, regardless of primary disease); hypotension (systolic blood pressure [BP] neurological condition. 5100 mmHg); a history of postural or any unexplained syncope; renal, hepatic, or pulmonary disease; or clinically significant deviations in standard laboratory tests. Female patients could not be pregnant or breastfeeding; those with Methods child-bearing potential were required to use an established Study design method of birth control.
Recommended publications
  • Create a Healing Environment for Patients with Pseudobulbar Affect by Maude Mcgill, Phd, RN-BC, and Marzell Mcgill, BA, LPN
    Strictly Clinical Create a healing environment for patients with pseudobulbar affect By Maude McGill, PhD, RN-BC, and Marzell McGill, BA, LPN tact their provider for prompt appropriate treatment. • Signs and symptoms include: Teach patients how to manage PBA • emotional responses (such as crying or laughing) for optimal quality of life. that don’t fit the situation • emotional episodes lasting longer than expected • sudden emotional outbursts (these outbursts can I just don’t understand why Mom is crying. When I include frustration, anger, laughter, or crying) walked in the room, she was happy and calm. Then, • moments of intense emotions that are out of the when I asked her about her day, her smile turned into patient’s control a frown and she started crying uncontrollably. I’ve nev - • facial expressions that don’t match the emotional er seen her cry like that. I’m concerned. response. EMOTIONS ARE NATURAL . We’ve all heard the cliché, “Emotions make us human.” People cry when they’re hurt and laugh when things are funny. However, mil - lions of people find that controlling their emotions is hard because of pseudobul - bar affect (PBA). PBA refers to inappropriate, involun - tary, or uncontrollable laughing or crying caused by the residual effects of a nervous system disorder. Al - though PBA is closely asso - ciated with post-stroke pa - tients, it can occur with any nervous system condition, including Alzheimer’s dis - ease, traumatic brain injury, and multiple sclerosis. Sci - entists have labeled PBA a disorder of emotional incon - tinence (patients can’t control their emotional respons - Navigating the new normal of PBA es).
    [Show full text]
  • Acetadote (Acetylcysteine) Injection Is Available As a 20% Solution in 30 Ml (200Mg/Ml) Single Dose Glass Vials
    NDA 21-539/S-004 Page 3 Acetadote® (acetylcysteine) Injection Package Insert NDA 21-539/S-004 Page 4 RX ONLY PRESCRIBING INFORMATION ACETADOTE® (acetylcysteine) Injection For Intravenous Use DESCRIPTION Acetylcysteine injection is an intravenous (I.V.) medication for the treatment of acetaminophen overdose. Acetylcysteine is the nonproprietary name for the N-acetyl derivative of the naturally occurring amino acid, L-cysteine (N-acetyl-L-cysteine, NAC). The compound is a white crystalline powder, which melts in the range of 104° to 110°C and has a very slight odor. The molecular formula of the compound is C5H9NO3S, and its molecular weight is 163.2. Acetylcysteine has the following structural formula: H CH3 N SH O COOH Acetadote is supplied as a sterile solution in vials containing 20% w/v (200 mg/mL) acetylcysteine. The pH of the solution ranges from 6.0 to 7.5. Acetadote contains the following inactive ingredients: 0.5 mg/mL disodium edetate, sodium hydroxide (used for pH adjustment), and Sterile Water for Injection, USP. CLINICAL PHARMACOLOGY Acetaminophen Overdose: Acetaminophen is absorbed from the upper gastrointestinal tract with peak plasma levels occurring between 30 and 60 minutes after therapeutic doses and usually within 4 hours following an overdose. It is extensively metabolized in the liver to form principally the sulfate and glucoronide conjugates which are excreted in the urine. A small fraction of an ingested dose is metabolized in the liver by isozyme CYP2E1 of the cytochrome P-450 mixed function oxidase enzyme system to form a reactive, potentially toxic, intermediate metabolite. The toxic metabolite preferentially conjugates with hepatic glutathione to form nontoxic cysteine and mercapturic acid derivatives, which are then excreted by the kidney.
    [Show full text]
  • The Promise of N-Acetylcysteine in Neuropsychiatry
    Review The promise of N-acetylcysteine in neuropsychiatry 1,2,3,4 5,6 1 1,2,4 Michael Berk , Gin S. Malhi , Laura J. Gray , and Olivia M. Dean 1 School of Medicine, Deakin University, Geelong, Victoria, Australia 2 Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia 3 Orygen Research Centre, Parkville, Victoria, Australia 4 The Florey Institute of Neuroscience and Mental Health, Victoria, Australia 5 Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia 6 CADE Clinic, Department of Psychiatry, Level 5 Building 36, Royal North Shore Hospital, St Leonards, 2065, Australia N-Acetylcysteine (NAC) targets a diverse array of factors with the pathophysiology of a diverse range of neuropsy- germane to the pathophysiology of multiple neuropsy- chiatric disorders, including autism, addiction, depression, chiatric disorders including glutamatergic transmission, schizophrenia, bipolar disorder, and Alzheimer’s and Par- the antioxidant glutathione, neurotrophins, apoptosis, kinson’s diseases [3]. Determining precisely how NAC mitochondrial function, and inflammatory pathways. works is crucial both to understanding the core biology This review summarises the areas where the mecha- of these illnesses, and to opening the door to other adjunc- nisms of action of NAC overlap with known pathophysi- tive therapies operating on these pathways. The current ological elements, and offers a pre´ cis of current literature article will initially review the possible mechanisms of regarding the use of NAC in disorders including cocaine, action of NAC, and then critically appraise the evidence cannabis, and smoking addictions, Alzheimer’s and Par- that suggests it has efficacy in the treatment of neuropsy- kinson’s diseases, autism, compulsive and grooming chiatric disorders.
    [Show full text]
  • (Acetylcysteine) Effervescent Tablets for Oral Solution Intratracheal Instillation Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION • See the Full Prescribing Information for instructions on how to use the These highlights do not include all the information needed to use nomogram to determine the need for loading and maintenance dosing. CETYLEV® safely and effectively. See full prescribing information for CETYLEV. Recommended Adult and Pediatric Dosage (2.3): • CETYLEV is for oral administration only; not for nebulization or CETYLEV (acetylcysteine) effervescent tablets for oral solution intratracheal instillation Initial U.S. Approval: 1963 • Loading dose: 140 mg/kg • Maintenance doses: 70 mg/kg repeated every 4 hours for a total of 17 ----------------------------INDICATIONS AND USAGE--------------------------- doses. CETYLEV is an antidote for acetaminophen overdose indicated to prevent or • lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of See Full Prescribing Information for weight-based dosage and preparation acetaminophen in patients with acute ingestion or from repeated and administration instructions. supratherapeutic ingestion. (1) Repeated Supratherapeutic Acetaminophen Ingestion (2.4): -----------------------DOSAGE AND ADMINISTRATION----------------------- • Obtain acetaminophen concentration and other laboratory tests to guide Pre-Treatment Assessment Following Acute Ingestion (2.1): treatment; Rumack-Matthew nomogram does not apply. Obtain a plasma or serum sample to assay for acetaminophen concentration at least 4 hours after ingestion. ----------------------DOSAGE FORMS AND STRENGTHS---------------------
    [Show full text]
  • A Randomized Placebo-Controlled Trial of N-Acetylcysteine for Cannabis Use Disorder in Adults
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Drug Alcohol Manuscript Author Depend. Author Manuscript Author manuscript; available in PMC 2018 August 01. Published in final edited form as: Drug Alcohol Depend. 2017 August 01; 177: 249–257. doi:10.1016/j.drugalcdep.2017.04.020. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults Kevin M. Graya, Susan C. Sonnea, Erin A. McClurea, Udi E. Ghitzab, Abigail G. Matthewsc, Aimee L. McRae-Clarka, Kathleen M. Carrolld, Jennifer S. Pottere, Katharina Wiestf, Larissa J. Mooneyg, Albert Hassong, Sharon L. Walshh, Michelle R. Lofwallh, Shanna Babalonish, Robert W. Lindbladc, Steven Sparenborgb,†, Aimee Wahlec, Jacqueline S. Kingc, Nathaniel L. Bakera, Rachel L. Tomkoa, Louise F. Haynesa, Ryan G. Vandreyi, and Frances R. Levinj aMedical University of South Carolina, Charleston SC bNational Institute on Drug Abuse Center for the Clinical Trials Network, Rockville MD cThe Emmes Corporation, Rockville MD dYale University, New Haven CT Correspondence: Kevin M. Gray, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 67 President Street, MSC861, Charleston, SC USA 29425, Phone: (843) 792-6330, Fax: (843) 792-8206, [email protected]. †Retired Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    [Show full text]
  • IHH Notification Form Guide
    Integrated Health Home Health Home Notification Form Guide Introduction This is to assist in providing the Health Home with information on criteria and how to enroll the member into an Integrated Health Home (IHH). Enrollment Criteria Member needs to 1. Be eligible for Medicaid. 2. Have 1 or more Serious Mental Illness (SMI) or Serious Emotional Disturbance (SED). 3. Meet the Functional Impairment (FI) as determined by a Licensed Mental Health Professional. SMI & SED Definitions Diagnosis must be determined by use the Diagnostic and Statistical Manual (DSM) of Mental Disorders published by the American Psychiatric Association or its most recent International Classification of Diseases (ICD). SMI is defined as an Adult that has a persistent or chronic mental illness, a behavioral, or emotional disorder that causes serious functional impairment and substantially interferes with or limits one or more major life activities including functioning in the family, school, employment or community. SMI may co-occur with substance use disorder, developmental, neurodevelopmental or intellectual disabilities but those diagnoses may not be the clinical focus for health home services. SED is defined by a Child having a diagnosable mental, behavioral or emotional disorder which results in a functional impairment that substantially interferes with or limits the child’s role or functioning in family, school, or community activities. SED may co-occur with substance use disorder, developmental, neurodevelopmental or intellectual disabilities but those diagnoses may not be the clinical focus for health home services. Mental Health Professional Definition Mental health professional meets all of the following conditions: 1. Holds at least a master’s degree in a mental health field including, but not limited to, psychology, counseling and guidance, psychiatric nursing and social work; or is a doctor of medicine or osteopathic medicine; and 2.
    [Show full text]
  • Nuedexta, INN-Dextromethorphan/Quinidine
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT NUEDEXTA 15 mg/9 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains dextromethorphan hydrobromide monohydrate, equivalent to 15.41 mg dextromethorphan and quinidine sulfate dihydrate, equivalent to 8.69 mg quinidine. Excipient with known effect: Each hard capsule contains 119.1 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule Brick red gelatin capsule, size 1, with “DMQ / 20-10” printed in white ink on the capsule. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications NUEDEXTA is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults (see section 4.4). Efficacy has only been studied in patients with underlying Amyotrophic Lateral Sclerosis or Multiple Sclerosis (see section 5.1). 4.2 Posology and method of administration Posology The recommended starting dose is NUEDEXTA 15 mg/9 mg once daily. The recommended dose titration schedule is outlined below: Week 1 (day 1-7): The patient should take one NUEDEXTA 15 mg/9 mg capsule once daily, in the morning, for the initial 7 days. Weeks 2-4 (day 8-28): The patient should take one NUEDEXTA 15 mg/9 mg capsule, two times per day, one in the morning and one in the evening, 12-hours apart, for 21 days. From Week 4 on: If the clinical response with NUEDEXTA 15 mg/9 mg is adequate, the dose taken in weeks 2-4 should be continued. 2 If the clinical response with NUEDEXTA 15 mg/9 mg is inadequate, NUEDEXTA 23 mg/9 mg should be prescribed, taken two times per day, one in the morning and one in the evening, 12 hours apart.
    [Show full text]
  • Delayed Dosing of Minocycline Plus N-Acetylcysteine Reduces Neurodegeneration in Distal Brain Regions and Restores Spatial Memor
    Manuscript bioRxiv preprint doi: https://doi.org/10.1101/2021.03.28.437090; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury Kristen Whitney 1,2, Elena Nikulina1, Syed N. Rahman1, Alisia Alexis1 and Peter J. Bergold1,2 1Department of Physiology and Pharmacology 2Program in Neural and Behavioral Science, School of Graduate Studies State University of New York-Downstate Health Sciences University, Brooklyn NY 11215 Corresponding Author: [email protected] Department of Physiology and Pharmacology, Box 29 State University of New York – Downstate Health Sciences University 450 Clarkson Avenue Brooklyn, NY 11215 Declarations of interest: none Abbreviations: CHI- closed head injury Contra- contralateral Ipsi- ipsilateral MAP2 -microtubule associated protein 2 MINO- minocycline MN12- MINO plus NAC first dosed 12 hours after injury MN72- MINO plus NAC first dosed 72 hours after injury NAC- N-acetylcysteine TBI- Traumatic brain injury 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.28.437090; this version posted March 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Multiple drugs to treat traumatic brain injury (TBI) have failed clinical trials. Most drugs lose efficacy as the time interval increases between injury and treatment onset. Insufficient therapeutic time window is a major reason underlying failure in clinical trials.
    [Show full text]
  • What's New in Psychopharmacology
    Wednesday, 3:00 – 4:30, F2 What's New in Psychopharmacology Joel M. Sanchez, MD [email protected] Objectives: Identify advances in clinical assessment and management of selected healthcare issues related to persons with developmental disabilities Notes: 4/7/2016 What’s New in Nuedexta Psychopharmacology • A new medication for pseudobulbar affect (PBA) • Pseudobulbar Affect: Joel M. Sanchez, M.D. • Frequent, uncontrollable outbursts of crying or laughing in people with certain neurologic conditions or brain injuries Diplomate of the American Board of Psychiatry and Neurology, Psychiatry • Episodes may occur several times per day and can last seconds to minutes Diplomate of the American Board of Psychiatry and Neurology, Child/Adolescent Psychiatry • “emotional incontinence” • “pathological laughing and crying” The Right Door for Hope, Recovery and Wellness Wedgwood Christian Services Turning Leaf Behavioral Health Services Community Mental Health Authority - CEI ADHD Medications Antidepressants • Stimulants • SSRIs • Adzenys XR-ODT (amphetamine extended release oral dissolving tablet) • Brintellix (vortioxetine) • Quillivant XR (methylphenidate extended release liquid) • Viibryd (vilazodone) • Daytrana (methylphenidate transdermal) • SNRIs • Non-Stimulants • Fetzima (levomilnacipran) • Clonidine (Catapres / Kapvay) • Pristiq (desvenlafaxine) • Guanfacine (Tenex / Intuniv) • Strattera (atomoxetine) Antipsychotics Blood Pressure Medications • Abilify Maintena & Aristada (aripiprazole) • What’s Old is New • Every 4 weeks or Every 4-6
    [Show full text]
  • Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats
    Minocycline Synergizes with N-Acetylcysteine and Improves Cognition and Memory Following Traumatic Brain Injury in Rats Samah G. Abdel Baki, Ben Schwab, Margalit Haber, Andre´ A. Fenton, Peter J. Bergold* Departments of Physiology and Pharmacology, State University of New York-Downstate Medical Center, Brooklyn, New York, United States of America Abstract Background: There are no drugs presently available to treat traumatic brain injury (TBI). A variety of single drugs have failed clinical trials suggesting a role for drug combinations. Drug combinations acting synergistically often provide the greatest combination of potency and safety. The drugs examined (minocycline (MINO), N-acetylcysteine (NAC), simvastatin, cyclosporine A, and progesterone) had FDA-approval for uses other than TBI and limited brain injury in experimental TBI models. Methodology/Principal Findings: Drugs were dosed one hour after injury using the controlled cortical impact (CCI) TBI model in adult rats. One week later, drugs were tested for efficacy and drug combinations tested for synergy on a hierarchy of behavioral tests that included active place avoidance testing. As monotherapy, only MINO improved acquisition of the massed version of active place avoidance that required memory lasting less than two hours. MINO-treated animals, however, were impaired during the spaced version of the same avoidance task that required 24-hour memory retention. Co- administration of NAC with MINO synergistically improved spaced learning. Examination of brain histology 2 weeks after injury suggested that MINO plus NAC preserved white, but not grey matter, since lesion volume was unaffected, yet myelin loss was attenuated. When dosed 3 hours before injury, MINO plus NAC as single drugs had no effect on interleukin-1 formation; together they synergistically lowered interleukin-1 levels.
    [Show full text]
  • As Sensitive Plasma Biomarkers of Oxidative Stress Received: 22 June 2018 Xiaoyun Fu1,2, Shelby A
    www.nature.com/scientificreports OPEN Cysteine Disulfdes (Cys-ss-X) as Sensitive Plasma Biomarkers of Oxidative Stress Received: 22 June 2018 Xiaoyun Fu1,2, Shelby A. Cate1, Melissa Dominguez1, Warren Osborn1, Tahsin Özpolat 1, Accepted: 6 November 2018 Barbara A. Konkle1,2, Junmei Chen1 & José A. López1,2 Published: xx xx xxxx We developed a high-throughput mass spectrometry–based method to simultaneously quantify numerous small-molecule thiols and disulfdes in blood plasma. Application of this assay to analyze plasma from patients with known oxidative stress (sickle cell disease and sepsis) and from a patient with sickle cell disease treated with the antioxidant N-acetylcysteine suggests that cysteine disulfdes, in particular protein-bound cysteine, serve as sensitive plasma biomarkers for the extent of oxidative stress and efectiveness of antioxidant treatment. Oxidative stress accompanies a wide variety of diseases1, including sickle cell disease (SCD), HIV/AIDS, and rheumatoid arthritis, and antioxidant therapy is emerging as a pharmacological strategy for treating diseases in which oxidative stress is known or suspected to be elevated2. Te ability to measure oxidative stress quantitatively is important for understanding disease mechanisms and monitoring the efectiveness of antioxidant treatments. Among biomarkers of oxidative stress, the ratio of reduced glutathione (GSH) to glutathione disulfde (GSSG) is frequently measured in various cell types, owing to the millimolar intracellular concentrations of these glu- tathione species and the broad availability of assays for their measurement, including many that are commercially available1,3,4. Despite these advantages, GSH/GSSG is not well suited as a plasma biomarker of oxidative stress due to the low plasma concentrations of GSH species, which are usually in the low micromolar range, and the low sensitivity of the assays.
    [Show full text]
  • N-Acetylcysteine As a Treatment for Addiction
    12 N-Acetylcysteine as a Treatment for Addiction Jennifer E. Murray1,2,*, Jérôme Lacoste3 and David Belin2,4 1Department of Experimental Psychology, University of Cambridge, Cambridge, 2INSERM European Associated Laboratory, Psychobiology of Compulsive Habits, 3Unité de Recherche Clinique Intersectorielle, Centre Hospitalier Henri-Laborit, Poitiers, 4INSERM U1084 - LNEC & Université de Poitiers, AVENIR Team Psychobiology of Compulsive Disorders, Poitiers, 1,2UK 2,3,4France 1. Introduction Drug addiction is a chronic relapsing disorder characterized by compulsive use despite negative consequences and relapses even after years of abstinence (Leshner, 1997). Criteria put forth by the American Psychiatric Association (2000) for diagnosing drug addiction require at least three of the following symptoms associated with drug use: tolerance; withdrawal; a loss of control over drug intake; unsuccessful attempts to reduce intake; a significant amount of time spent acquiring, using, or recovering from the substance; reduced interest in social or work activities; and continued use despite awareness of adverse physical and psychological consequences (American Psychiatric Association, 2000). In the United States, 22.5 million people, or 8.9% of the population meets the criteria for substance dependence or abuse (Substance Abuse and Mental Health Services Administration, 2010), and in Europe, drug, and especially cocaine, use has been increasing over the last ten years in the general population, with a more pronounced trend in young individuals (EMCDDA, 2009), suggesting that cocaine addiction may continue to spread in western countries. Worldwide estimates suggest more than 8% of the population have an alcohol use disorder and more than 2% have an illicit drug use disorder (World Health Organization, 2010).
    [Show full text]